Quote:

---

n this Phase 2 study, 34% (19 of 56 patients) treated with leronlimab compared to 50% (14 of 28 patients) treated with placebo reported at least one adverse event. A total of 19 serious adverse events (SAEs) were reported during the study. Eleven (11) SAEs were reported in 6 patients (6/28; 21.4%) receiving placebo compared to eight ( SAEs in 5 patients (5/56; 8.9%) receiving leronlimab. None of the SAEs in the leronlimab arm were deemed related to study drug administration by the investigators. Of the 84 patients treated, one patient died 33 days after enrollment due to an event unrelated to leronlimab.

---

Parse out the stats related to the number of people versus the number of events and AE vs SAE and it makes sense.

Study subjects with AE
19/56 = 34% Tx'd with Lero
14/28 = 50% Placebo

Study subjects with SAE
5/56 = 8.9% Lero Arm
6/28 = 21.4% Placebo Arm

Total # of SAE in each arm
8 Lero
11 Placebo (x2 weighted so equivalent to 22 versus

MAV